Arcutis Biotherapeutics (ARQT) to Release Earnings on Tuesday

Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to be posting its Q3 2025 results before the market opens on Tuesday, October 28th. Analysts expect Arcutis Biotherapeutics to post earnings of ($0.09) per share and revenue of $86.6910 million for the quarter. Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. Arcutis Biotherapeutics had a negative return on equity of 62.62% and a negative net margin of 35.40%.The firm had revenue of $81.50 million for the quarter, compared to analyst estimates of $72.70 million. On average, analysts expect Arcutis Biotherapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Arcutis Biotherapeutics Trading Up 0.1%

Shares of ARQT stock opened at $20.11 on Friday. The business’s fifty day moving average price is $18.11 and its 200 day moving average price is $15.57. Arcutis Biotherapeutics has a 1-year low of $8.21 and a 1-year high of $21.84. The firm has a market capitalization of $2.41 billion, a PE ratio of -26.81 and a beta of 2.06. The company has a debt-to-equity ratio of 0.77, a current ratio of 3.20 and a quick ratio of 3.04.

Insiders Place Their Bets

In other news, insider Larry Todd Edwards sold 4,504 shares of the company’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $20.04, for a total value of $90,260.16. Following the sale, the insider directly owned 178,897 shares in the company, valued at $3,585,095.88. This represents a 2.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Patrick Burnett sold 2,438 shares of the company’s stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $15.57, for a total value of $37,959.66. Following the completion of the sale, the insider owned 104,811 shares in the company, valued at $1,631,907.27. This represents a 2.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 154,386 shares of company stock valued at $2,640,187. Insiders own 9.40% of the company’s stock.

Hedge Funds Weigh In On Arcutis Biotherapeutics

Large investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC lifted its position in Arcutis Biotherapeutics by 169.2% during the second quarter. Squarepoint Ops LLC now owns 167,814 shares of the company’s stock worth $2,353,000 after buying an additional 105,487 shares during the period. Engineers Gate Manager LP lifted its position in Arcutis Biotherapeutics by 47.6% during the second quarter. Engineers Gate Manager LP now owns 97,605 shares of the company’s stock worth $1,368,000 after buying an additional 31,482 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Arcutis Biotherapeutics by 3.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,417 shares of the company’s stock worth $1,118,000 after buying an additional 2,063 shares during the period. Brevan Howard Capital Management LP lifted its position in Arcutis Biotherapeutics by 8.2% during the second quarter. Brevan Howard Capital Management LP now owns 43,934 shares of the company’s stock worth $616,000 after buying an additional 3,316 shares during the period. Finally, CANADA LIFE ASSURANCE Co lifted its position in Arcutis Biotherapeutics by 101.5% during the second quarter. CANADA LIFE ASSURANCE Co now owns 25,829 shares of the company’s stock worth $363,000 after buying an additional 13,013 shares during the period.

Analysts Set New Price Targets

ARQT has been the topic of a number of recent analyst reports. Wall Street Zen raised Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Arcutis Biotherapeutics in a report on Tuesday, October 14th. Needham & Company LLC upped their price objective on Arcutis Biotherapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, August 7th. The Goldman Sachs Group initiated coverage on Arcutis Biotherapeutics in a report on Friday, July 25th. They set a “neutral” rating and a $18.00 price objective on the stock. Finally, Cowen reiterated a “buy” rating on shares of Arcutis Biotherapeutics in a research report on Thursday, August 7th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $19.80.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.